Dianiklin

Dianiklin
IUPAC ime
	(5aS,8S,10aR)-5a,6,9,10-Tetrahidro,7H,11H-8,10a-metanopirido[2',3':5,6]pirano[2,3-d]azepin
Identifikatori
CAS broj	292634-27-6
ATC kod	none
PubChem	CID 9816447
UNII	Y0SNM34C6O
Hemijski podaci
Formula	C13H16N2O
Molarna masa	216,278
	SMILES C4CN3CCC1Oc2cccnc2CC14C3; ;

Dianiklin (SSR-591,813) je lek koji je razvilo preduzeće Sanofi-Aventis. On deluje kao parcijalni agonist na neuronskim nikotinskim acetilholinskim receptorima. On je selektivan za podtip α4β2. Ovaj ligand je razvijen za primenu u tretmanu nikotinske zavisnosti kao pomoć u suzbijanju želje za pušenjem.^[1] Dianiklin je veoma sličan vareniklinom, koji se raznije pojavio na tržištu. Dianiklin ima manje izražene nuspojave. On je uspešno prošao kroz Fazu II kliničkih ispitivanja. Razvoj leka je prekinut zbog nepovoljnog ishoda kliničkih ispitivanja u Fazi III.^[2]^[3]^[4]

Reference[уреди | уреди извор]

^ Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. Journal of Pharmacology and Experimental Therapeutics. 2003 Jul;306(1):407-20. PMID 12682217
^ Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.
^ Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
^ Sanofi Pipeline Архивирано на сајту Wayback Machine (4. децембар 2008)

Spoljašnje veze[уреди | уреди извор]

[1] Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. Journal of Pharmacology and Experimental Therapeutics. 2003 Jul;306(1):407-20. PMID 12682217

[2] Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.

[3] Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation

[4] Sanofi Pipeline Архивирано на сајту Wayback Machine (4. децембар 2008)

[1]

[2]

[3]

[4]